InsidersTradesSigma
Total declarations
Companies
▲ Purchases (31 ops.)
▼ Sales (2 ops.)
Explore the full record of transactions filed by BAKER BROS. ADVISORS LP, Board Member / Investor Representative. Insider active across 11 companies, notably Seagen Inc.. Cumulatively, 61 filings have been logged. Total volume traded: €36.9m. The latest transaction was disclosed on 30 June 2022 — Attribution. Regulator: SEC (Form 4). All data is accessible without signup.
Declarations61 total
0433 shares0
Common Stock
SEC:0001209191-22-040235:0·
010,000 shares0
Class A Common Shares
SEC:0001209191-22-039905:0·
033,384 shares0
Ordinary Shares
SEC:0001209191-22-039274:0·
02,144 shares0
Common Stock
SEC:0001209191-22-037929:0·
1,252,432 shares
Ordinary Shares
SEC:0001209191-22-036411:0·
017,104 shares0
Common Stock
SEC:0001209191-22-035496:0·
€8,7161,247 shares@ €6.98940.0004% mcap0.1% of flow
Common Stock
SEC:0001209191-22-034577:0·
Ideal exit: 27 Feb 2023 (T+270)
€1,510279 shares@ €5.41360.0006% mcap8.4% of flow
Common Stock
SEC:0001209191-22-034576:0·
Ideal exit: 27 Feb 2023 (T+270)
€34,7755,688 shares@ €6.11370.0015% mcap0.3% of flow
Common Stock
SEC:0001209191-22-032582:0·
Ideal exit: 19 Feb 2023 (T+270)
€4,875883 shares@ €5.52120.0020% mcap27.2% of flow
Common Stock
SEC:0001209191-22-031723:0·
Ideal exit: 14 Feb 2023 (T+270)
€62,41311,410 shares@ €5.470.0027% mcap0.5% of flow
Common Stock
SEC:0001209191-22-030150:0·
Ideal exit: 10 Feb 2023 (T+270)
€11,5132,063 shares@ €5.58090.0046% mcap64.3% of flow
Common Stock
SEC:0001209191-22-030168:0·
Ideal exit: 10 Feb 2023 (T+270)
01,503 shares0
Common Stock
SEC:0001209191-22-029574:0·
€65,85040,800 shares@ €1.6140.10% mcap2.4% of flow
Common Stock
SEC:0001209191-22-028579:0·
Ideal exit: 4 Feb 2023 (T+270)
0440 shares0
Common Stock
SEC:0001209191-22-022469:0·
€405,87920,000 shares@ €20.29390.0021% mcap10.4% of flow
Common Stock
SEC:0001209191-22-018023:0·
€323,09217,500 shares@ €18.46245.1% of flow
Common Stock
SEC:0001209191-22-017900:0·
€432,5037,300 shares@ €59.24690.0023% mcap11.1% of flow
Common Stock
SEC:0001209191-22-011843:0·
Ideal exit: 14 Nov 2022 (T+270)
€21,123441 shares@ €47.89790.0009% mcap0.2% of flow
Common Stock
SEC:0001209191-22-010914:0·
Ideal exit: 12 Nov 2022 (T+270)
€21,123441 shares@ €47.89790.2% of flow
Common Stock
SEC:0001209191-22-010914·
Ideal exit: 12 Nov 2022 (T+270)
€2m40,164 shares@ €58.28160.012% mcap59.8% of flow
Common Stock
SEC:0001209191-22-009411:0·
Ideal exit: 7 Nov 2022 (T+270)
€4m86,479 shares@ €46.28570.17% mcap31.4% of flow
Common Stock
SEC:0001209191-22-005629:0·
Ideal exit: 24 Oct 2022 (T+270)
€4m86,479 shares@ €46.285731.6% of flow
Common Stock
SEC:0001209191-22-005629·
Ideal exit: 24 Oct 2022 (T+270)
€5m102,207 shares@ €50.004840.4% of flow
Common Stock
SEC:0001209191-22-004852·
Ideal exit: 18 Oct 2022 (T+270)
€5m102,207 shares@ €50.00480.22% mcap40.0% of flow
Common Stock
SEC:0001209191-22-004852:0·
Ideal exit: 18 Oct 2022 (T+270)
25 of 61 declarations
About BAKER BROS. ADVISORS LP
BAKER BROS. ADVISORS LP is a life sciences and biotechnology-focused investment firm with a long-standing reputation in U.S. healthcare investing. In public company filings, the firm appears primarily as a significant investor, board participant, or governance influencer rather than as an operating executive team. Its most visible role in listed companies is typically that of a board member, shareholder representative, or strategic investor with meaningful influence over governance, capital allocation, and long-term corporate direction. In terms of career path, Baker Bros. Advisors LP has built its profile around concentrated, research-driven investments in biopharmaceutical companies. Public disclosures show a durable presence across several healthcare names, including BeiGene, Incyte Corp., Seagen Inc., and Kodiak Sciences Inc. Across these relationships, the firm’s involvement is generally tied to oversight of clinical strategy, development priorities, financing decisions, and governance matters. Notable decisions associated with the firm’s activity include support for research and development programs, shareholder votes on governance structures, and participation in important growth phases of portfolio companies. Public records also indicate a board presence at Kodiak Sciences Inc. and a long-running role at Seagen Inc. until Seagen’s acquisition by Pfizer in December 2023. More broadly, Baker Bros. Advisors LP is widely recognized for its expertise in scientific diligence, specialized investing, and supporting biotechnology companies through multiple stages of development. Where precise executive-level biographical detail is not clearly supported by the available sources, the description remains intentionally general to avoid invention.
